HANGZHOU, China, Oct. 26 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. , one of mainland China’s leading pharmaceutical companies, today announced the Company plans to initiate an integrated marketing campaign reaching a worldwide audience consisting of news media, the scientific and financial communities and entities in the public, private, and government sectors.
“Aida Pharmaceuticals’ expertise in research and development, manufacturing and supply chain management enables us to safely and effectively bring industry-changing products to market, capitalizing on emerging growth opportunities. Aida Pharmaceuticals already markets and sells the antibiotic Etimicin Sulfate, to the Chinese public. Additionally, Aida is currently a major player in the global marketplace in the development of the genetic therapy Rh-Apo2L, a potentially revolutionary treatment for various forms of cancer. We have received awards for our contributions and advancement of the Chinese biomedical community and remain committed to our mission and are excited about our future. In addition to our flagship antibiotic and the continuously positive progress of Rh-Apo2L, we believe our pipeline of genetic therapies and drug treatments represent some of the most advanced biotechnology development in China. We are ready to tell the world about our plans for further commercialization and distribution of our therapies in China,” stated Jin Biao, Chairman of Aida.
Aida will kick-off its campaign with a press conference on Wednesday, November 1, 2006 at 3:00 PM CCT (2:00 AM EST) at Aida Pharmaceuticals’ headquarters in Hangzhou, China. The press conference will follow a seminar for invited scientists and doctors to discuss Phase I trial results of the Company’s prospective cancer treatment, Rh-Apo2L, and Aida Pharmaceuticals’ intention to commence Phase II and III trials. Mr. Jin Biao, Chairman of Aida Pharmaceuticals, along with Chinese government officials, will address the press. Information and details will also be made available that day via a press release.
As previously announced, Aida Pharmaceuticals has launched an English corporate website, http://en.aidapharma.com. Interested parties can learn about the Aida management team, their corporate vision, development plans and the Company’s planned pipeline of genetic and drug therapies currently being researched and developed by the Company. Aida intends to make all trial information for Rh-Apo2L, in addition to other company updates, available via this site. Investors and financial media contacts can view and download investor relations materials at http://www.equityperformancegroup.com/clients_aida.php.
Aida Pharmaceuticals is currently developing an interactive executive presentation. This web-based service will provide a complete presentation on all aspects of the Company, including its operations, product lines, research and development capabilities, financial overview, future objectives, growth prospects, etc. The presentation will be available for download and viewing by year-end 2006, via the Company’s Investor Relations website, http://www.equityperformancegroup.com/clients_aida.php.
Aida Pharmaceuticals’ management team is in the preliminary stages of planning a North American media and investor tour in 2007. The Company’s executives intend to visit several North American cities to further educate the media and investment community about the Company’s established products, ongoing research and development plans and the attainment of previously disclosed growth objectives. As Aida moves forward with its Global Marketing Campaign, the Company will make announcements as information becomes available.
About Aida Pharmaceuticals:
Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company’s mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. Aida is now producing and marketing a patented prescription drug in China: Etimicin Sulfate. It is the first antibiotic developed in China and is regarded as a category “A” drug by the State Food and Drug Administration of China.
Contact Information: Company: Aida Pharmaceuticals, Inc. 31 Dingjiang Road Jianggan District Hangzhou, China 310016 Investor Relations: Equity Performance Group Bethany Tomich (617) 723-1465 Bethany@equityperfgp.comhttp://www.equityperformancegroup.com Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995:
This press release includes certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management’s current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, clinical trial results, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations is detailed in its filings with the United States Securities and Exchange Commission available at http://www.sec.gov.
Aida Pharmaceuticals, Inc.
CONTACT: Bethany Tomich of the Equity Performance Group for AidaPharmaceuticals, +1-617-723-1465, Bethany@equityperfgp.com
